Literature DB >> 15530693

Oral immunization of Carassius auratus with modified recombinant A-layer proteins entrapped in alginate beads.

Sarah Maurice1, Amos Nussinovitch, Nicole Jaffe, Oded Shoseyov, Arieh Gertler.   

Abstract

This study was focused on the utilization of a recombinant expression system to produce a unique modified subunit vaccine possessing a self-contained delivery system which could potentially improve the uptake and delivery of vaccine products as well their immunogenic potential. For this purpose the A-layer protein (At-R) associated with the fish pathogen atypical Aeromonas salmonicida was cloned and modified by the genetic fusion of the protein transduction domain (MTS) derived from Kaposi fibroblast growth factor (At-MTS). The potential for these proteins to be employed as antigens for oral immunization of goldfish was examined by encapsulation of At-R, At-MTS and the control, BSA, into biodegradable alginate gel macrospheres which were fed to goldfish in place of standard pellet fish feed. The bead physical properties were modified only in the presence of At-R and the temporal release of proteins was significantly less when At-MTS was employed. Western blot analysis of serum samples collected from fish following intubation with the recombinant proteins determined that the rate of protein uptake from the digestive tract into the blood system improved considerably when MTS was fused to At-R. Experimental fish were fed one of three protein-alginate formulae on a schedule of 3 days/week or 5 days/month for a period of 2 months. After 1 month, animals fed on the 5-day protocol demonstrated increased serum antibody titers while following an additional month of feeding this level decreased and titers were found to be higher in fish maintained on the 3-day regime. Fish fed At-MTS maintained the highest titer at the end of 2-month period. To determine whether the diminished antibody titers were a result of oral tolerance fish were injected intraperitoneally with the At-R antigen. Only experimental groups which had been fed At-R or At-MTS demonstrated increased antibody titers which paralleled a typical secondary humoral response. In spite of the presence of an increased titer to A-protein, vaccinated fish did not demonstrate resistance to infection with atypical A. salmonicida.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530693     DOI: 10.1016/j.vaccine.2004.06.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Baculovirus-mediated GCRV vp7 and vp6 genes expression in silkworm and grass carp.

Authors:  Bo Liu; Yongchang Gong; Zhen Li; Xiaolong Hu; Guangli Cao; Renyu Xue; Chengliang Gong
Journal:  Mol Biol Rep       Date:  2016-04-16       Impact factor: 2.316

2.  IPNV Antigen Uptake and Distribution in Atlantic Salmon Following Oral Administration.

Authors:  Lihan Chen; Øystein Evensen; Stephen Mutoloki
Journal:  Viruses       Date:  2015-05-21       Impact factor: 5.048

3.  Augmentation of the antibody response of Atlantic salmon by oral administration of alginate-encapsulated IPNV antigens.

Authors:  Lihan Chen; Goran Klaric; Simon Wadsworth; Suwan Jayasinghe; Tsun-Yung Kuo; Øystein Evensen; Stephen Mutoloki
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

Review 4.  Protection of Teleost Fish against Infectious Diseases through Oral Administration of Vaccines: Update 2021.

Authors:  Jarl Bøgwald; Roy A Dalmo
Journal:  Int J Mol Sci       Date:  2021-10-10       Impact factor: 5.923

Review 5.  An Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for Finfish.

Authors:  Hetron Mweemba Munang'andu; Stephen Mutoloki; Øystein Evensen
Journal:  Front Immunol       Date:  2015-10-22       Impact factor: 7.561

Review 6.  Oral Vaccination of Fish - Antigen Preparations, Uptake, and Immune Induction.

Authors:  Stephen Mutoloki; Hetron Mweemba Munang'andu; Øystein Evensen
Journal:  Front Immunol       Date:  2015-10-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.